Nasdaq GlobeNewswire

Italy's First Center of Robotic Excellence Established in Northern Italy at Villa Beretta Centro di Riabilitazione

Del

FREIBURG, Germany and RICHMOND, Calif., Aug. 09, 2017 (GLOBE NEWSWIRE) -- "Villa Beretta" Centro di Riabilitazione, in Costa Masnaga (LC), Italy, has been established as the first Center of Robotic Excellence in Europe by Ekso Bionics Holdings, Inc., an industry leader in exoskeleton technology for medical and industrial use. Villa Beretta was one of the first European adopters of state-of-the-art exoskeleton technology for rehabilitation, such as the EksoGT(TM), the first exoskeleton cleared by the U.S. FDA and to receive a CE Mark in Europe for use with stroke and spinal cord injuries from L5 to C7.

Dr. Franco Molteni, Director of Department of Rehabilitation Medicine, Villa Beretta, notes, "We look forward to mentoring our peers on using the EksoGT, which is becoming a cornerstone of our rehabilitation program because it allows patients to stand up and walk earlier, which has a tremendous impact on their mood and motivation. As the patient progresses in the rehabilitation process, the EksoGT will adjust to their development and the clinical team have the possibility to easily customize the device after each patient to improve patient outcome with an intelligent supported gait. We strongly believe that sharing our knowledge on this life-changing technology will not only benefit today's patients, but provide new rehabilitation opportunities for tomorrow's patients."

As a Center of Excellence, Villa Beretta is committed to provide peer-to-peer support as a reference site to train other European facilities interested in becoming proficient in innovative approaches to rehabilitation. Villa Beretta will also work with Ekso Bionics and three leading U.S. rehabilitation facilities to aid research and development efforts to advance the use of innovative exoskeleton technology for mobility-impaired patients. In addition, Villa Beretta will gather clinical evidence and measureable results on rehabilitation with EksoGT and create research protocols for proving standard of care for exoskeletons for rehabilitation.

"Villa Beretta is one of our first European customers for the EksoGT, as well as a leader in the rehabilitation community for stroke and spinal cord injuries," said Matthias Stief, president and managing director of Ekso Bionics Europe GmbH. "We're proud to welcome Villa Beretta as one of our Centers of Excellence, who will play an indispensable role in training other European rehabilitation centers who are eager to bring exoskeletons to their facilities so they can help their patients get back on their feet earlier."

To learn more about the Centers of Excellence and the EksoGT, visit http://eksobionics.com/eksohealth/centers-of-excellence/

About Villa Beretta Centro di Riabilitazione
Villa Beretta Centro di Riabilitazione in Costa Masnaga, Italy provides high-quality medical care and rehabilitation for individuals with traumatic brain injury, spinal cord injury, stroke and neuromuscular disease. Villa Beretta is measuring the impact that robotic exoskeletons could make on a stroke patient's efforts to regain walking ability.

Ekso Bionics®
Ekso Bionics is a leading developer of exoskeleton solutions that amplify human potential by supporting or enhancing strength, endurance and mobility across medical, industrial and defense applications. Founded in 2005, the company continues to build upon its unparalleled expertise to design some of the most cutting-edge, innovative wearable robots available on the market. Ekso Bionics is the only exoskeleton company to offer technologies that range from helping those with paralysis to stand up and walk, to enhancing human capabilities on job sites across the globe, to providing research for the advancement of R&D projects intended to benefit U.S. defense capabilities. The company is headquartered in the Bay Area and is listed on the Nasdaq Capital Market under the symbol EKSO. For more information, visit: www.eksobionics.com.

About Ekso GT(TM)
Ekso GT(TM) is the first exoskeleton cleared by the U.S. FDA and receive a CE Mark in Europe for use with stroke and spinal cord injuries from L5 to C7. The EksoGT with SmartAssist(TM) software is the only exoskeleton available for rehabilitation institutions that can provide adaptive amounts of power to either side of the patient's body, challenging the patient as they progress through their continuum of care. The suit's patented technology provides the ability to mobilize patients earlier, more frequently and with a greater number of high intensity steps. To date, this device has helped patients take more than 70 million steps in over 130 rehabilitation institutions around the world.

Media Contact:
Carrie Yamond
917-371-2320
cyamond@lazarpartners.com

Investor Contact:
David Carey
212-867-1768
investors@eksobionics.com



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Ekso Bionics via Globenewswire

Om Nasdaq GlobeNewswire

Nasdaq GlobeNewswire
Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700http://www.nasdaqomx.com

NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra Nasdaq GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Nasdaq GlobeNewswire

CrownBio Launches an Innovative Grant Program to Fund Advancements in Preclinical Oncology Research17.11.2017 18:07Pressemelding

SANTA CLARA, Calif., Nov. 17, 2017 (GLOBE NEWSWIRE) -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:ticker 6554) and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, announces the launch of a grant program supporting oncology research scientists which provides funding for projects that show promise for scientific advancement of Patient Derived Xenograft (PDX) technology. Research Grants up to $50,000 will be awarded to projects focused on accelerating the pace of preclinical innovation and novel PDX methodologies that improve clinical predictions with sound science. The program offers an opportunity for investigators to receive funding for projects that may not receive support through traditional funding channels. Submitted proposals will be reviewed and selected by CrownBio's Scientific Steering Committee with the goa

Barings Backs Sentinel Capital Partners in Acquisition of Nekoosa17.11.2017 17:00Pressemelding

CHARLOTTE, N.C., Nov. 17, 2017 (GLOBE NEWSWIRE) -- Barings, one of the world's leading asset management firms, announced today that it served as Lead Agent on a senior secured credit facility to support Sentinel Capital Partners in its acquisition of Nekoosa ("Nekoosa" or the "Company"). Headquartered in Nekoosa, Wisconsin, the Company is a leading manufacturer of specialty paper and film products used in the graphics and commercial print markets, including application and pressure-sensitive tapes, specialty synthetic papers, sheeted digital and offset grade carbonless paper, and extruded film products. Nekoosa serves a highly diverse base of more than 70,000 commercial print and graphics shops in 65 countries. Barings served as lead senior lender on the transaction, which included a senior term loan and a revolving credit facility. "Sentinel is pleased to have Barings' support on our investment in Nekoosa," said Scott Perry, a partner with Sentinel Capital Partner

At SC17, ExaScaler and PEZY Computing Unveil Gyoukou Supercomputer with a High Combined Green500/Top500 Ranking16.11.2017 23:29Pressemelding

ExaScaler and PEZY Computing Also Take Top Three Green500 Positions DENVER, Nov. 16, 2017 (GLOBE NEWSWIRE) -- At SC17, ExaScaler and PEZY Computing unveiled their Gyoukou supercomputer whose Green500 and Top500 rankings attest to a unique combination of high efficiency and computing power. The Gyoukou supercomputer is installed at the Yokohama Research Institute in Japan. (Video: PEZY Liquid immersion cooling) PEZY supercomputers leverage 48V Factorized Power, a high efficiency, high density power distribution architecture. PEZY's CPUs are co-packaged with Vicor's Power-on-Package ("PoP") Modular Current Multipliers ("MCMs"), which enable efficient, direct 48V to sub-1V current multiplication at the XPU. ExaScaler and PEZY Computing also achieved the #1, #2 and #3 positions on the Green500. These supercomputer system installations also utilize 48V Factorized Power. Come see us at SC17 at Booth 633 where ExaScaler / PEZY Computing will be

ELS Educational Services, Inc. Launches New Vacation English Program Starting January 201816.11.2017 20:59Pressemelding

New York, New York, Nov. 16, 2017 (GLOBE NEWSWIRE) -- ELS Educational Services, Inc. - one of the leading language services providers worldwide - has launched a new vacation English language program, ELS Language Experience+, which is set to begin enrollment for January 2018. "Here at ELS, our students and their English language goals always come first, and we are proud to introduce ELS Language Experience+ as an exciting new addition to the many quality programs we offer them," said ELS Chief Operating Officer, Reiji Terasaka. "This conversation-oriented, flexible new vacation English program allows students to make the most of their English instruction while gaining an invaluable cultural experience at the same time." ELS Language Experience+ concentrates on everyday speaking, communication skills and discussion, within a flexible course structure (three or six hours of study per day). Courses offered include: Everyday English, Grammar in Action, D

Global SD-WAN Partnership between CallTower and Aryaka to Deliver High-Performance Cloud Communication Solutions to Global Enterprises16.11.2017 16:02Pressemelding

SAN MATEO, Calif., Nov. 16, 2017 (GLOBE NEWSWIRE) -- Aryaka, the leading global SD-WAN provider, today announced a new partnership with CallTower, an industry-leading unified communications and collaboration company, to provide global enterprise customers with fast and reliable, high-quality cloud service connectivity.  CallTower's partnership with Aryaka will deliver improved performance of their unified communications solutions to global enterprise customers. CallTower has linked their data centers with the Aryaka global network to deliver secure, reliable connectivity with quality of service guarantees for mission critical real-time communication applications. CallTower Cisco and Microsoft unified communications solutions, including Cloud Contact Center customers will now be able to add Aryaka's global SD-WAN service to further optimize, and enhance reliability over a secure network.  "In addition to our unified communications offering, we have seen tremendous growth i

Gunvor Secures US $1.39 Billion Revolving Credit Facility16.11.2017 15:00Pressemelding

Gunvor Group Ltd / Gunvor Secures US $1.39 Billion Revolving Credit Facility . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement. Strong bank support for Group strategy results in substantial over-subscription GENEVA, Nov. 16, 2017 (GLOBE NEWSWIRE) -- Gunvor Group Ltd ("Gunvor" or the "Group") has signed a US $1.39 billion Revolving Credit Facility ("RCF") in favour of Gunvor International B.V. and Gunvor SA (the "Borrowers"). The RCF, launched at US $1 billion, was substantially over-subscribed, drawing in US $1.81 billion, a record high for the facility. The RCF was scaled back to accommodate the needs of the Group, which will use the funds to finance general corporate purposes and working capital requirements. "Gunvor continues to receive considerable support from both its exis

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom